Patents by Inventor Paul E. Morin

Paul E. Morin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL PD-L1 BINDING POLYPEPTIDES FOR IMAGING
    Publication number: 20190343972
    Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
    Type: Application
    Filed: July 24, 2019
    Publication date: November 14, 2019
    Inventors: Paul E. Morin, David Donnelly, Dasa Lipovsek, Jochem Gokemeijer, Maria N. Jure-Kunkel, David Fabrizio, Martin C. Wright, Douglas Dischino, Samuel J. Bonacorsi, JR., Ralph Adam Smith, Virginie Lafont, Daniel Cohen
  • PD-L1 binding polypeptides for imaging
    Patent number: 10406251
    Abstract: Provided herein are novel polypeptides comprising fibronectin type III tenth (10Fn3) domains which specifically bind to Programmed Death Ligand-1 (PD-L1), as well as imaging agents based on the same for diagnostics.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: September 10, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul E. Morin, David Donnelly, Dasa Lipovsek, Jochem Gokemeijer, Maria N. Jure-Kunkel, David Fabrizio, Martin C. Wright, Douglas Dischino, Samuel J. Bonacorsi, Jr., Ralph Adam Smith, Virginie Lafont, Daniel Cohen
  • MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF
    Publication number: 20190256570
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Application
    Filed: February 27, 2019
    Publication date: August 22, 2019
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof
    Patent number: 10377806
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: August 13, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul E. Morin, Daniel Cohen, Ranjan Mukherjee, Timothy P. Reilly, Rose C. Christian, Dasa Lipovsek, Ray Camphausen, John Krupinski
  • SERUM ALBUMIN BINDING MOLECULES
    Publication number: 20190203248
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: January 10, 2019
    Publication date: July 4, 2019
    Inventors: Michael L. GOSSELIN, David FABRIZIO, Joanna F. SWAIN, Tracy MITCHELL, Ray CAMPHAUSEN, Sharon T. CLOAD, Eric FURFINE, Paul E. MORIN, Ranjan MUKHERJEE, Simeon I. TAYLOR
  • PET IMAGING WITH PD-L1 BINDING POLYPEPTIDES
    Publication number: 20190184042
    Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
    Type: Application
    Filed: May 31, 2017
    Publication date: June 20, 2019
    Inventors: Paul E. MORIN, David DONNELLY, Dasa LIPOVSEK, Jochem GOKEMEIJER, Maria JURE-KUNKEL, David FABRIZIO, Martin C. WRIGHT, Douglas DISCHINO, Samuel J. BONACORSI, Jr., Ralph Adam SMITH, Virginie LAFONT, Daniel COHEN, David K. LEUNG
  • Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
    Patent number: 10266578
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: April 23, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • METHODS AND COMPOSITIONS FOR DEUTERATED BIOLOGICS
    Publication number: 20190099506
    Abstract: Deuterated polymer-biomolecule conjugates and the synthesis and use of deuterated polymer-biomolecule conjugates for detecting the location of specific molecules, e.g., cell surface molecules, in a subject, and for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
    Type: Application
    Filed: October 1, 2018
    Publication date: April 4, 2019
    Inventors: Michael J. Smith, Haiying Tang, Paul E. Morin, Harold J. Malone
  • Serum albumin binding molecules
    Patent number: 10221438
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: March 5, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
  • PRODRUGGABLE ANTIBODIES, PRODRUGS THEREOF, AND METHODS OF USE AND MAKING
    Publication number: 20190055321
    Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
    Type: Application
    Filed: August 14, 2018
    Publication date: February 21, 2019
    Inventors: Stanley R. Krystek, JR., Yong Zhang, Gregory D. Vite, Arvind Rajpal, Chetana Rao-Naik, Paul E. Morin, Mohan Srinivasan, Zheng Lin, Virginie Lafont, Alla Pritsker
  • Therapeutic uses of modified FGF-21 polypeptides
    Patent number: 10189883
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: January 29, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul E. Morin, Daniel Cohen, Ranjan Mukherjee, Timothy P. Reilly, Rose C. Christian, Dasa Lipovsek, Ray Camphausen, John Krupinski
  • Modified FGF-21 Polypeptides and Uses Thereof
    Publication number: 20180243375
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Application
    Filed: May 15, 2018
    Publication date: August 30, 2018
    Inventors: Paul E. Morin, Daniel Cohen, Ranjan Mukherjee, Timothy P. Reilly, Rose C. Christian, Dasa Lipovsek, Ray Camphausen, John Krupinski
  • MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF
    Publication number: 20180222960
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 9, 2018
    Inventors: Gene M. DUBOWCHIK, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • NOVEL PD-L1 BINDING POLYPEPTIDES FOR IMAGING
    Publication number: 20170258948
    Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
    Type: Application
    Filed: November 24, 2015
    Publication date: September 14, 2017
    Inventors: Paul E. MORIN, David DONNELLY, Dasa LIPOVSEK, Jochem GOKEMEIJER, Maria N. JURE-KUNKEL, David FABRIZIO, Martin C. WRIGHT, Douglas DISCHINO, Samuel J. BONACORSI, Jr., Ralph Adam SMITH, Virginie LAFONT, Daniel COHEN
  • MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF
    Publication number: 20170189486
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Application
    Filed: March 16, 2017
    Publication date: July 6, 2017
    Inventors: Paul E. MORIN, Daniel COHEN, Ranjan MUKHERJEE, Timothy P. REILLY, Rose C. CHRISTIAN, Dasa LIPOVSEK, Ray CAMPHAUSEN, John KRUPINSKI
  • SERUM ALBUMIN BINDING MOLECULES
    Publication number: 20170145464
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: November 29, 2016
    Publication date: May 25, 2017
    Inventors: Michael L. GOSSELIN, David FABRIZIO, Joanna F. SWAIN, Tracy MITCHELL, Ray CAMPHAUSEN, Sharon T. CLOAD, Eric FURFINE, Paul E. MORIN, Ranjan MUKHERJEE, Simeon I. TAYLOR
  • Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
    Patent number: 9631004
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: April 25, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul E. Morin, Daniel Cohen, Ranjan Mukherjee, Timothy P. Reilly, Rose C. Christian, Dasa Lipovsek, Ray Camphausen, John Krupinski
  • Modified FGF-21 Polypeptides Comprising an Internal Deletion and Uses Thereof
    Publication number: 20170029479
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Application
    Filed: July 20, 2016
    Publication date: February 2, 2017
    Inventors: Paul E. MORIN, Daniel COHEN, Ranjan MUKHERJEE, Timothy P. REILLY, Rose C. CHRISTIAN, Dasa LIPOVSEK, Ray CAMPHAUSEN, John KRUPINSKI
  • Serum albumin binding molecules
    Patent number: 9540424
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: January 10, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukerjee, Simeon I. Taylor
  • Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
    Patent number: 9434778
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: September 6, 2016
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul E. Morin, Daniel Cohen, Ranjan Mukherjee, Timothy P. Reilly, Rose C. Christian, Dasa Lipovsek, Ray Camphausen, John Krupinski